{
    "clinical_study": {
        "@rank": "139580", 
        "acronym": "HNJ-NKAES-2012", 
        "arm_group": {
            "arm_group_label": "Activated natural killer cells", 
            "arm_group_type": "Experimental", 
            "description": "Activated natural killer cells"
        }, 
        "brief_summary": {
            "textblock": "To determine safety profile of immunotherapy with natural killer cells and activated\n      expanded (NKAEs) after salvage chemotherapy in relapsed/refractory paediatric T cell\n      lymphoblastic leukaemia and lymphoma."
        }, 
        "brief_title": "Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Lymphoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged between 0 and 21 years with relapsed or refractary acute lymphoblastic\n             leukemia or T-cell lymphoblastic lymphoma.\n\n          -  Lansky Index > 60%.\n\n          -  Left ventricular ejection fraction > 39%.\n\n          -  Negative HIV serology.\n\n          -  Provide informed consent in accordance with current legislation.\n\n        Exclusion Criteria:\n\n          -  Patients with a history of poor compliance.\n\n          -  Patients not valid after psycho-social evaluation\n\n          -  Severe (4) functional organ disorders (hepatic, renal, respiratory) according to NCI\n             CTCAE v3 criteria"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01944982", 
            "org_study_id": "HNJ-NKAES-2012", 
            "secondary_id": "2012-000054-63"
        }, 
        "intervention": {
            "arm_group_label": "Activated natural killer cells", 
            "intervention_name": "Expanded haploidentical natural killer cells (NKAEs)", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Immunotherapy", 
            "NKAEs", 
            "Expanded haploidentical natural killer cells", 
            "Activated natural killer cells"
        ], 
        "lastchanged_date": "May 3, 2014", 
        "location": {
            "contact": {
                "email": "aperezmartinez@salud.madrid.org", 
                "last_name": "Antonio P\u00e9rez-Mart\u00ednez, MD", 
                "phone": "+34917277223"
            }, 
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28046"
                }, 
                "name": "Pediatric Hematology-Oncology; Hospital Infantil Universitario La Paz"
            }, 
            "investigator": {
                "last_name": "Antonio P\u00e9rez Mart\u00ednez, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma.", 
        "overall_contact": {
            "email": "aperezmartinez@salud.madrid.org", 
            "last_name": "Antonio P\u00e9rez-Mart\u00ednez, MD, PhD", 
            "phone": "+34917277223"
        }, 
        "overall_official": {
            "affiliation": "Service of Pediatric Hematology-Oncology", 
            "last_name": "Antonio P\u00e9rez-Mart\u00ednez, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety profile (number of AEs per patient)", 
            "safety_issue": "Yes", 
            "time_frame": "Two months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01944982"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Universitario La Paz", 
            "investigator_full_name": "Antonio Perez-Martinez", 
            "investigator_title": "Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of episodes of febrile neutropenia, bacteriemia or viral or fungal infections", 
                "safety_issue": "Yes", 
                "time_frame": "During 14 months"
            }, 
            {
                "description": "hematological recovery: neutrophils >500/mm3, lymphocytes >250/mm3 and platelets >50.000/mm3)", 
                "measure": "time to hematological recovery (days)", 
                "safety_issue": "Yes", 
                "time_frame": "2 months"
            }, 
            {
                "measure": "days of hospitalization in each cycle", 
                "safety_issue": "Yes", 
                "time_frame": "2 months"
            }, 
            {
                "description": "Objective response rate according to cytomorphic and by \"minimal residual disease\" criteria (cytometry and/or real time PCR)", 
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "measure": "days of isolation", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }
        ], 
        "source": "Hospital Infantil Universitario Ni\u00f1o Jes\u00fas, Madrid, Spain", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital Infantil Universitario Ni\u00f1o Jes\u00fas, Madrid, Spain", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}